111 (YI) EBITDA (2017 - 2025)

111 (YI) posted EBITDA of -$46000.0 for Q4 2025, up 85.67% sequentially from -$321000.0 in Q3 2025, and up 95.41% YoY from -$23539.8 in Q4 2024.

111 (YI) EBITDA (2017 - 2025) Analysis & Trends

111 has reported EBITDA for 9 years, with the latest figure at -$46000.0 in Q4 2025.

Quarterly EBITDA rose 95.41% year-over-year to -$46000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$333918.9 (down 207.72% YoY) and the FY2025 annual result came in at -$330766.3, down 214.45% from the prior year.
EBITDA climbed to -$46000.0 in Q4 2025 per YI's latest filing, from -$321000.0 in the prior quarter.
Over five years, EBITDA peaked at $516000.0 in Q1 2024 and troughed at -$29.2 million in Q2 2021.
A 5-year average of -$10.2 million and a median of -$8.4 million in 2023 frame the typical range for EBITDA.
The sharpest annual moves came in 2024 and 2025: EBITDA surged 116.31% in 2024, then tumbled 195.25% in 2025.
Over 5 years, EBITDA stood at -$16.4 million in 2021, then advanced by 4.01% to -$15.7 million in 2022, then plunged by 85.06% to -$29.1 million in 2023, then jumped by 96.55% to -$1.0 million in 2024, then surged by 95.41% to -$46000.0 in 2025.
According to Business Quant data, EBITDA over the past three periods registered -$46000.0, -$321000.0, and $13134.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Mckesson	100.02 Bn	94.85 Bn	3.69 Bn	1.32 Bn
2	Cencora	60.88 Bn	58.06 Bn	3.61 Bn	1.27 Bn
3	Cardinal Health	54.14 Bn	49.29 Bn	2.56 Bn	729.00 Mn
4	Henry Schein	10.05 Bn	9.90 Bn	1.10 Bn	171.00 Mn
5	Akso Health	737.16 Mn	736.96 Mn	-	-
6	Edap Tms	159.12 Mn	137.58 Mn	7.34 Mn	-8.03 Mn
7	Accendra Health	100.85 Mn	93.20 Mn	263.41 Mn	-35.15 Mn
8	111	32.10 Mn	-26.65 Mn	18.18 Mn	-2.88 Mn
9	Cosmos Health	12.73 Mn	10.29 Mn	1.51 Mn	-2.81 Mn
10	VitaNova Life Sciences	11.51 Mn	9.91 Mn	264,662.00	-109,860.00

Download Data